Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

467
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
467
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

442
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
442
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

400
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
400
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

649
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
649
Heart Failure VII: Nursing Interventions01:30

Heart Failure VII: Nursing Interventions

576
The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...
576
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

1.1K
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Worsening versus advanced heart failure: Management and challenges.

ESC heart failure·2025
Same author

Editorial Commentary: Spotlight on ATTR cardiomyopathy: the unexpected journey of a once considered "orphan disease".

Trends in cardiovascular medicine·2025
Same author

Obesity, Challenges, and Weight-Loss Strategies for Patients With Ventricular Assist Devices.

JACC. Heart failure·2024
Same author

State of the art on angiotensin-neprilysin inhibitors.

Minerva cardiology and angiology·2024
Same author

Management of hypertension in heart transplant recipients: an ongoing conundrum.

Current opinion in cardiology·2024
Same author

Torsemide vs Furosemide Among Patients With New-Onset vs Worsening Chronic Heart Failure: A Substudy of the TRANSFORM-HF Randomized Clinical Trial.

JAMA cardiology·2023

Related Experiment Video

Updated: Feb 24, 2026

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

7.1K

Changing our Approach to Stage D Heart Failure.

Miriam F Becnel1, Hector O Ventura2, Selim R Krim2

  • 1Division of Cardiology, John Ochsner Heart and Vascular Institute, New Orleans, LA, United States; Section of Cardiomyopathy & Heart Transplantation, John Ochsner Heart and Vascular Institute, Ochsner Clinic Foundation, 1514 Jefferson Highway, New Orleans, LA 70121, United States.

Progress in Cardiovascular Diseases
|August 13, 2017
PubMed
Summary

This paper offers a practical guide for managing advanced heart failure (HF) patients unresponsive to optimal therapy. It emphasizes early referral and discusses a potential shift towards left ventricular assist device (LVAD) therapy.

Keywords:
Heart failureHeart transplantationLeft ventricular assist deviceMechanical circulatory support

More Related Videos

A Modified Technique for Transverse Aortic Constriction in Mice
04:52

A Modified Technique for Transverse Aortic Constriction in Mice

Published on: August 18, 2022

5.9K
Implantation of Total Artificial Heart in Congenital Heart Disease
07:27

Implantation of Total Artificial Heart in Congenital Heart Disease

Published on: July 18, 2014

25.3K

Related Experiment Videos

Last Updated: Feb 24, 2026

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

7.1K
A Modified Technique for Transverse Aortic Constriction in Mice
04:52

A Modified Technique for Transverse Aortic Constriction in Mice

Published on: August 18, 2022

5.9K
Implantation of Total Artificial Heart in Congenital Heart Disease
07:27

Implantation of Total Artificial Heart in Congenital Heart Disease

Published on: July 18, 2014

25.3K

Area of Science:

  • Cardiology
  • Advanced Heart Failure Management

Background:

  • Despite progress, many heart failure patients reach advanced, refractory stages.
  • Optimal medical therapy is insufficient for a subset of end-stage heart failure patients.

Purpose of the Study:

  • To provide a practical approach for managing Stage D heart failure (HF) patients.
  • To discuss available therapies and considerations for advanced HF management.
  • To explore the role of left ventricular assist device (LVAD) therapy in advanced HF.

Main Methods:

  • Review of current therapeutic options for Stage D HF.
  • Discussion of patient identification, risk stratification, and evaluation strategies.
  • Analysis of the evolving landscape of heart transplantation and LVAD therapy.

Main Results:

  • Optimal medical therapy is often inadequate for advanced heart failure.
  • Early referral to specialized centers is crucial for effective management.
  • Left ventricular assist device (LVAD) therapy presents a viable alternative to transplantation.

Conclusions:

  • A paradigm shift towards LVAD therapy may be necessary for advanced HF.
  • Timely intervention and specialized care are critical for improving outcomes in Stage D HF patients.
  • The evolving allocation system necessitates a reevaluation of treatment strategies.